Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer
For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS), ...
Jan 29, 2024
0
0